|
|
|
Volumn 118, Issue 1227, 2005, Pages
|
|
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
DACARBAZINE;
DRUG DERIVATIVE;
TEMOZOLOMIDE;
DRUG APPROVAL;
ECONOMICS;
ETHICS;
GLIOBLASTOMA;
HUMAN;
NEW ZEALAND;
NOTE;
PUBLIC HEALTH;
SOCIAL PSYCHOLOGY;
TERMINAL CARE;
ANTINEOPLASTIC AGENTS, ALKYLATING;
DACARBAZINE;
DRUG APPROVAL;
GLIOBLASTOMA;
HUMANS;
NATIONAL HEALTH PROGRAMS;
NEW ZEALAND;
SOCIAL VALUES;
TERMINAL CARE;
|
|
EID: 33644829656
PISSN: None
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
